Caspase-3 activity has been described to be essential for druginduced apoptosis. Recent results suggest that in addition to its downstream executor function, caspase-3 is also involved in the processing of upstream caspase-8 and -9. To test the absolute requirement for caspase-3, we examined mitomycin C (MMC)-induced apoptosis in the caspase-3 deficient human breast cancer cell line MCF-7. MMC was used as anticancer drug since this agent was preferentially active compared to chemotherapeutic compounds with differing mechanisms of action such as cisplatin, docetaxel, or lovastatin. MMC treatment led to pronounced caspase-8, -9, and -7 processing and early morphological features of apoptosis within 48 h. This could be inhibited by the broad-spectrum caspase inhibitor z-VAD.fmk and to a lesser extent by z-IETD.fmk and z-LEHD.fmk, which have a certain preference for inhibiting caspase-8 and -9, respectively. MMC induced apoptosis in MCF-7 cells was not mediated by the death receptor pathway as demonstrated by experiments using the inhibiting anti-Fas antibody ZB4 and transfections with CrmA, a viral serpin inhibitor of caspase-8, and the dominant negative Fasassociated death domain (FADD-DN). Stable expression with Bcl-2 significantly prevented the processing of caspase-9 but also of caspase-8 and blocked the induction of apoptosis. Thus, we provide evidence that caspase-3 activity is dispensable for MMC-induced apoptosis and for caspase-8 and -9 processing in MCF-7 cells.
Introduction
DNA damaging agents are an integral component in the treatment of a large variety of solid and hematological malignancies. DNA damage is a classical inducer of p53 function, which orchestrates apoptosis or DNA repair depending on the cellular background. However, p53 is one of the most frequently mutated genes suggesting that other p53-independent pathways of apoptosis induction are operational for DNA damaging anticancer drugs. 1 ± 3 It has been proposed that the Fas (CD95) signaling pathway is involved in chemotherapy induced apoptosis. 4 ± 6 Drugs such as doxorubicin or methotrexate have been shown to induce upregulation of Fas receptor as well as Fas ligand expression, thus leading to autocrine and paracrine Fas-dependent apoptosis. Drug-induced apoptosis can be prevented by Fas neutralizing antibodies and a dysfunctional Fas pathway has been shown to correlate with insensitivity to anticancer agents in cell lines. However, various groups were not able to corroborate these findings 7, 8 and the importance of the Fas pathway in chemotherapy-induced apoptosis remains controversial. 9 ± 12 Apoptosis is characterized by a series of stereotype morphological features such as chromatin condensation, nuclear fragmentation, and the appearance of membraneenclosed apoptotic bodies. These morphological changes are executed by a family of aspartate-specific cysteine proteases (caspases) which can be activated by various apoptogenic signals. In the classical model, 13, 14 caspases are divided into initiator caspases (such as caspase-8, -9) and executioner caspases (caspase-3, -6, -7) according to their function and their sequence of activation. The initiator caspases appear to display some specificity according to the type of apoptotic signal. Two main activation cascades for apoptosis induction have been described. 15 ± 17 Fas receptor-ligand interactions use caspase-8 activation to trigger the downstream executioner caspases. An alternative mitochondrial pathway, which is triggered by various anticancer agents, involves activation of caspase-9 upon recruitment to the mitochondria by cytochrome c and apoptosis protease activation factor-1 (APAF-1).
More downstream, the initiator caspases lead to the activation of executioner caspases -3, -6, and -7, which in turn cleave specific proteins resulting in the typical hallmarks of apoptosis. Caspase-3 seems to play a central role in chemotherapy-induced apoptosis. It is specifically required for DNA fragmentation leading to the typical apoptotic pattern of DNA laddering. 18, 19 Caspase-3 is also necessary for other typical morphological features of apoptotic cell death. 20 In certain systems, such as UVirradiation and osmotic shock of embryonic stem cells or chemotherapy of mouse embryonic fibroblasts, caspase-3 activity seems even to be an indispensable requirement for the occurrence of apoptosis. 21 In addition, caspase-3 is involved in activating the other effector caspases-6 and -7 as shown in caspase-3 reconstitution experiments of caspase-3 deficient MCF-7 cells. 22 The temporal and hierarchical order of the activation of the caspase cascade has been questioned by recent observations. Blanc et al. have published data to suggest that caspase-3 is not only involved in executing the apoptosis phenotype but is also essential for the processing of upstream procaspase-9 in cisplatin-induced apoptosis. 23 In contrast to this finding, Engels et al. found in the same human breast cancer MCF-7 cell line, that anticancer drug-induced caspase-8 processing but not caspase-9 processing was critically dependent on the presence of caspase-3 activity. 24 Another recent paper has corroborated downstream caspase-8 activation by caspase-3 in a B-cell lymphoma system. 25 These results suggest that downstream executioner caspases can amplify the function of upstream initiator caspases. Additional amplifying loops might be in place between the classical Fas signal transduction pathway and the mitochondrial/cytochrome c/ APAF-1 pathway of apoptosis induction.
We therefore asked the question, how these pathways interact in anticancer drug-induced apoptosis in the well described system of the human breast cancer cell line MCF-7. Mitomycin C (MMC) was used as anticancer drug since this agent was preferentially active in MCF-7 cells compared to chemotherapeutic compounds with differing mechanisms of action such as cisplatin, docetaxel, or lovastatin. MCF-7 cells lack caspase-3 due to a 47-base pair deletion within exon 3 of the CASP-3 gene, 20 which allowed us to examine whether caspase-3 is central for the feedback activation of initiator caspases -8 and -9 for executioning apoptosis. Despite recent findings to show otherwise, we found caspase-8 and -9 activation in the absence of caspase-3 activity.
Results
Induction of apoptosis with MMC in the human breast cancer cell line MCF-7
To determine the cytotoxic effect of various anticancer drugs with different mechanisms of action in MCF-7 cells, the dose response over 5 days was assessed using the Trypan Blue exclusion assay (Figure 1 ). The viability of MCF-7 cells was decreased by 87% after 72 h treatment with 5 mg/ml MMC. In comparison, cisplatin led to a 31%, taxotere to a 25%, and lovastatin to a 17% decrease in viability, respectively. Thus, since MMC has shown the most potent cytotoxic activity, this drug was used to induce apoptosis in further experiments.
Apoptotic cell death is defined by the occurrence of a stereotype phenotype including cell shrinkage, chromatin condensation and nuclear fragmentation. However, Johnson et al. have identified an early nuclear morphological change in caspase-3 null MCF-7 cells, which precedes chromatin condensation during chemical-induced apoptosis. 26 To verify, that decrease of viability correlated with the induction of apoptotic cell death in this system, MMC treated cells were stained with the DNA intercalating Hoechst 33342 dye. This experiment showed that 82% of MMC treated MCF-7 cells underwent nuclear condensation (Figure 2a ). Since apoptosis is executed by caspases, we used the promiscuous cell membrane permeable caspase inhibitor z-VAD.fmk as an apoptosis specific blocking agent. As shown in (Figure 2b,c) , apoptotic cell death could be largely prevented by coadministering z-VAD.fmk with MMC. To assess whether the different treatments did affect viability rather than mere apoptotic phenomena, we performed clonogenic growth assays. The results of these experiments showed that adding z-VAD.fmk to MMC treated cells did significantly increase clonogenic survival in addition to preventing apoptotic morphology ( Figure 2d , Table 1 ). These results confirm that the cytotoxic activity of MMC results mainly from the induction of the apoptosis machinery, which is dependent on the activation of the caspase cascade. Caspase-3 independent caspase-8, -9 and -7 processing with MMC treatment
The initiator caspases -8 and -9 are activated by proapoptotic signals such as Fas receptor stimulation or cytotoxic agents respectively. There is also recent evidence that the effector caspase-3 itself is involved in caspase-8 and -9 activation. 23 ± 25 This led us to test caspase-8 and -9 activation in MCF-7 cells, which are devoid of caspase-3 activity. Since chemotherapy typically leads to caspase-9 activation by engaging cytochrome c and APAF-1 at the mitochondrial membrane, 27 we examined caspase-9 activation by MMC in the MCF-7 cells. Caspase-9 activation was assessed by verifying the cleaving of the caspase-9 49-kDa proform to the characteristic 35 kD fragment. This 35 kD fragment appeared within 24 h of MMC treatment as detected by Western blotting ( Figure 3a ) suggesting a role of caspase-9 activation for MMC induced apoptosis in MCF-7 cells. Caspase-8, which is the most apical caspase in the Fas death signaling pathway was also activated by MMC as shown by the appearance of the typical p41/42 fragment and a lower size fragment of around 26 kD (Figure 3a) . However, this caspase-8 processing appeared only after 36 h suggesting an activation independent or downstream of caspase-9. Caspase-7, which is another effector caspase, was also activated by MMC treatment and processed into the typical p20 fragment within 36 h (Figure 3a ). Procaspase-6 was upregulated by MMC treatment but displayed no evidence of activation ( Figure  3a ). Figure 3b shows the pattern of caspase-8 and -9 activation upon treatment with various anticancer agents with differing mechanism of action. MMC led to a preferential cleaving of caspase-8.
Caspase-8 processing after MMC treatment is not dependent upon Fas activation
Caspase-8 is the classical initiator caspase of the Fas pathway, which is stimulated by Fas receptor/ligand interactions. The Fas pathway has also been shown to contribute to chemotherapy-induced apoptosis in various cellular systems. 4 ± 6 Since Fas receptor upregulation is associated with drug-induced activation of the Fas death signaling pathway, Fas receptor expression changes were assessed by immunoblotting. MMC treatment did not lead to an induction of the Fas receptor (Figure 4a ). To further explore the involvement of the Fas pathway in druginduced apoptosis, cells were cotreated with MMC and ZB4, an inhibiting anti-Fas antibody that blocks Fas mediated killing. 9 This antibody failed to prevent apoptosis (Figure 4b ). In addition, MCF-7 cells were transfected with the adapter molecule Fas associated death domain dominant negative (FADD-DN; 28, 29 ) and with CrmA. 30 Both did neither protect from MMC-induced apoptosis ( Figure  5d and Table 1 ) nor inhibit caspase-8 or -9 activation (Figure 4c ). All these experiments supported the notion 
Impact of various caspase inhibitory peptides and apoptosis inhibiting proteins on MMC induced apoptosis
Alternative activators had to contribute to caspase-8 activation because of the fact that we found no evidence for the involvement of the Fas receptor or caspase-3 in MCF-7 cells.
Since processing of caspase-9 occurred earlier than processing of caspase-8 in our system, we looked at the possibility of caspase-9 dependent processing of caspase-8. For this purpose, we used z-IETD.fmk, an inhibitor of caspase-8, and z-LEHD.fmk, an inhibitor of caspase-9, which have been described to be specific for the respective caspase. 31 MMC induced caspase-8 processing was completely blocked by z-IETD.fmk without effect on the processing of caspase-9 ( Figure 5a ). The caspase-9 inhibitor z-LEHD.fmk, on the other hand, had no effect on the accumulation of the cleaved caspase-9 itself but led to a near complete inhibition of caspase-8 activation. This lacking specificity of z-LEHD.fmk has recently been corroborated by other investigators. 32 The caspase-8 inhibitor z-IETD.fmk had a stronger blocking effect than z-LEHD.fmk on MMC induced apoptosis (Figure 5b,c) . However, for both inhibitors and also less toxic concentrations of MMC, this effect was less than 30% limiting the strength of these results concerning conclusions on the impact of the respective caspase. This interpretation is corroborated by the results of the clonogenic growth assays, where both caspase inhibitors had no effect on clonogenic survival in contrast to the potent impact of z-VAD.fmk (Table 1) . DEVD, which inhibits caspases-3 family members, 33 YVAD, which inhibits caspase-1 family members 34 and the apoptosis inhibitory protein XIAP 35 did all not prevent MMC-induced apoptosis ( Figure 5d and Table 1 ).
Overexpression of Bcl-2 protects MCF-7 cells from MMC-induced apoptosis and processing of caspase-8 and -9
Bcl-2 inhibits release of cytochrome c from mitochondria preventing the activation of caspase-9 and apoptosis. 36 We determined if the processing of caspase-9 or other caspases, which were activated by MMC treatment in MCF-7 cells, was inhibited by enforced Bcl-2 expression. Both control cells, which had been transfected with an empty vector (MCF-7va) and two clones of cells overexpressing Bcl-2 (MCF-7/Bcl-2) (Figure 5f ) were treated with MMC and apoptosis was quantified by Hoechst staining (Figure 6a 
Discussion
The results of these experiments add further evidence for the complexity of the interplay of different caspases in drug induced apoptosis. In accordance with other recently published work, 8, 24, 25, 37 we demonstrate that the role of caspase-8 is not restricted to death receptor induced apoptosis, but is also crucially involved in chemotherapy induced cell death. Although different reports demonstrate that cytotoxic drugs induce apoptosis by triggering Fas signalling, the conflicting data from the literature suggest that the involvement of this pathway is dependent on the cellular background. We found no evidence for the involvement of the Fas death pathway in MMC-induced apoptosis in MCF-7 cells. This is in line with other reports on a disabled Fas pathway in this cell line, 38 which is not induced by DNA damaging agents such as MMC. 39 Our results suggest a purely intracellular mechanism of caspase-8 activation analogous to the activation of caspase-9 within the apoptosome.
Various lines of evidence suggest that caspase-8 was activated downstream from caspase-9 in our system. Firstly, the analysis of the temporal activation pattern revealed that the processing of caspase-9 was initiated before caspase-8 processing. Secondly, the preferential caspase-9 peptide inhibitor z-LEHD.fmk had a pronounced blocking effect on caspase-8 processing. Thirdly, Bcl-2 blocked caspase-9 but also caspase-8 cleavage despite the fact, that Bcl-2 has shown not to inhibit Fas induced caspase-9 signaling. 40 However, Fas-independent caspase-8 activation might still be blocked by Bcl-2. An alternative hypothesis to the sequential activation of caspase-9 and -8 would be that caspase-8 is activated independently or in parallel with caspase-9. This is in line with other recent studies, which have shown that caspase-8 activation in response to cytotoxic drugs is mediated by mitochondria rather than the Fas pathway. 37, 41 In various systems such as the lung cancer cell line H460 or neuroblastoma cells, a scenario has been suggested, that APAF-1 together with cytochrome c and caspase-8 could form an alternative apoptosomal complex. 37, 41 Also, it has been described that caspase-3 activates caspase-8 via Caspase-3 independent caspase-8 and -9 activation F Pirnia et al caspase-6. 42 This is consistent with the lack of caspase-6 activation in our system.
A recent report places caspase-8 cleavage downstream of caspase-3 activation and describes functionally relevant block of caspase-8 processing, if B-lymphoid cells are depleted of caspase-3. 25 Although our experiments do not exclude the possibility, that caspase-8 would have been more extensively or rapidly cleaved in the presence of active caspase-3, we found pronounced and functionally relevant caspase-8 processing induced by MMC treatment in the MCF-7 human breast cancer cell line, which is devoid of caspase-3 protein. 20 Our results also show, that caspase-9 processing is not dependent on caspase-3 activity in contrast to the conclusions of a recent paper by Blanc et al., which postulates an essential function of caspase-3 for caspase-9 processing. 23 Thus, other caspases can clearly replace the lack of caspase-3 function in MCF-7 cells. The mutual activation capacity of different caspases seems to be more pronounced than formerly appreciated. Although specific caspases have their preferential activation partners, this partnership seems not to be exclusive and might be influenced by the expression pattern of the various caspases and interacting molecules in the respective cell.
Two groups have recently reported their work on the functional impact of restoring caspase-3 activity by transfection in MCF-7 cells. 22, 43 Both found that restoring caspase-3 activity translated into a significantly higher activity of the anticancer drugs etoposide, doxorubicin, epirubicin and taxol. In contrast, even high drug concentrations led to only sporadic islands of cell death in caspase-3 defective cells suggesting a crucial role for this enzyme in drug-induced apoptosis. 22 Doxorubicin, epirubicin, and etoposide are inhibitors of topoisomerase II, 44, 45 while taxol interacts with tubulin metabolism. 46 It can be speculated, that drugs with other mechanisms of action might be less dependent on caspase-3 activity for apoptosis induction. In support of this notion, we found a 40% higher cytotoxic activity of MMC as used in our experiments in comparison to doxorubicin at the concentrations used by Yang et al. in wild-type MCF-7 cells (Pirnia et al., unpublished results). MMC led to an exclusive activation of caspase-8 but not of caspase-9 in comparison to various other drugs with differing mechanisms of action at concentrations formerly established as equitoxic in the NCI/ ADR-RES cell line (Figure 3b) . 47 This suggests a caspase-9 independent caspase-8 activation, which correlates well with the preferential cytotoxic activity of MMC in this system. Since MMC as a DNA damaging agent is a very strong activator of p53 function compared to taxol and other anticancer drugs (Pirnia et al., unpublished results), 48, 49 our findings could be interpreted in the context of recent data, which show p53 to be crucially involved in the transcriptional activation of APAF-1. 50 Thus, the potent p53 stimulatory effect of MMC resulting in transcriptional activation of death pathway components may override the lack of caspase-3 function.
The promising observation by Friedrich and Wieder et al. that procaspase-3 overexpression restores sensitivity for drug-induced apoptosis without affecting background apoptosis provides hope that the therapeutic modulation of caspase-3 activity is not toxic by itself. 43 Thus, replacing or enforcing the function of individual caspases might serve as a therapeutic tool for increasing the efficacy of cytotoxic anticancer agents. In addition, our results suggest that the caspase activation cascade is not an uniform machinery, where one missing component leads to a functional shutdown, but rather a redundant system. The type of inducing stimulus might override the lack of an individual caspase as shown here for MMC in the case of lacking caspase-3 activity.
Materials and Methods
Cell culture, anticancer drugs, expression constructs, and transfections
The human mammary carcinoma cell line MCF-7 (obtained from ATCC, Rockville, MD, USA) was grown at 378C in RPMI 1640 medium containing 10% (v v) heat-inactivated fetal bovine serum, 100 units/ml penicillin G, 100 mg/ml streptomycin, and 2 mM glutamine in an atmosphere containing 5% (v v) CO 2 ). Taxotere (40 mg/ml) was purchased from Rho Ã ne-Poulenc Rorer (Thalwil, Switzerland), cisplatin (0.5 mg/ml) and mitomycin C (0.5 mg/ml) from Bristol-Myers Squibb (Baar, Switzerland) and lovastatin was a kind gift from Merck, Sharp and Dohme Research Pharmaceuticals Co. (Syracuse, NY, USA). Lovastatin (10 mM) was converted from the inactive lactone form into its active dihydroxy open acid form as described. 51 MCF-7 human breast cancer cells were transfected by the calcium phosphate method with either plasmid pCdeltaj-SV-2 (vector-only) or pCdeltaj-bcl-2 (bcl-2) that had been generously provided by Y. Tsujimoto. 52 Following transfection, the cells were selected in 1 g/l G418 until individual colonies appeared. Clones were collected separately and analyzed for Bcl-2 expression by Western blot (Figure 5f ). The pcDNA3CrmA wildtype was a generous gift from M. Tewari 53 and pDNA3 XIAP (myctagged) from Q. Deveraux. 54 The AU1 FADD Dominant Negative pcDNA3 was a generous gift from V. Dixit. 55 The pEGFP-N1 plasmid (GFP) was purchased from BD CLONTECH (Basel, Switzerland). MCF-7 cells were transfected using TransFast 2 (Promega Corporation, Basel, Switzerland) according to the manufacturer's protocol. Transfection efficiency assessed by co-transfection with a green fluorescent protein (GFP) expression vector was between 30 ± 50%. The Western blot confirming the ectopic expression of XIAP-myc, FADD-DN, and Bcl-2 is shown in Figure 5f . Since the CrmA plasmid was non-tagged, transfection efficiency was assessed using FACS quantification of GFP (Figure 5e ). After 36 h, GFP positive cells were quantified by flow cytometry (Becton Dickinson, CA, USA).
Caspase inhibitors
The caspase inhibitory peptides benzyloxycarbonyl-Val-Ala-Aspfluoromethyl keton (z-VAD.fmk), Ac-Asp-Glu-Val-aspartic acid aldehyde (DEVD), and Ac-Tyr-Val-Ala-Asp-chloromethylketone (YVAD) was obtained from Bachem (Bubendorf, Switzerland). The inhibitors zlle-Glu(OMe)-Thr-Asp(OMe)-FMK (z-IETD.fmk) and z-Leu-Glu(OMe)-His-Asp-(OMe)-FMK (z-LEHD.fmk) were purchased from Enzyme System Products (CA, USA). Caspase inhibitors were used at a concentration of 40 mM for (z-IETD.fmk and z-LEHD.fmk) and 100 mM for (z-VAD.fmk), DEVD, and YVAD 2 h prior to chemotherapy exposure.
Apoptosis assay
Cells were detached with 5 mM EDTA, cytospinned onto glass, and fixed with 3.7% formaldehyde for 15 min at RT. Staining was performed with 1 mg/ml Hoechst 33342 in PBS. Coverslips
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Caspase-3 independent caspase-8 and -9 activation F Pirnia et al were mounted on the slides with Slowfade (Molecular Probes, Oregon, USA). The cells were examined on a Leica DMRB photomicroscope using a 1006magnification lens. To quantify apoptotic cells, 300 nuclei were counted for each experimental condition.
Cell viability assay
Cell viability was determined by Trypan blue exclusion. Fifty per cent of cell suspension was mixed with 50% of Trypan blue isotonic solution (0.2%; w v), and cell viability was determined on a haemocytometer under a microscope.
Clonogenic assays
MCF-7 cells were seeded in triplicate into six-well plates at a concentration of 300 cells per well. After 24 h, MMC were added at a final concentration corresponding to the IC 80 , IC 50 and IC 30 for 48 h. After drug removal, cells were washed twice with PBS and allowed to proliferate in fresh medium. Colonies were counted when they reached the size of 50 ± 100 cells, after staining with 0.1% crystal violet in 0.9% saline for 30 min at room temperature. The number of colony-forming units in treated cultures was expressed as the percentage on untreated controls. The respective inhibitors were added 2 h prior to MMC treatment.
Western blot analysis
Cells were collected and lysed with TNN lysis buffer (40 mM Tris, pH 8.0, 120 mM NaCl, 0.5% Nonidet P-40, 0.1 mM sodium orthovanadate, 2 mg/ml aprotinin, 2 mg/ml leupeptine, and 100 mg/ml PMFS) at 48C for 1 h. Lysates were spun at 14 000 r.p.m. for 20 min to remove cellular debris. Protein concentration was determined with the BCA reagent (Pierce, IL, USA). Equal amounts of protein were subjected to electrophoresis on SDS-polyacrylamide gels and transferred to nitrocellulose membranes (Schleicher & Schuell, Dassel, Germany) by electroblotting. The blots were blocked, probed for 1 h with the primary antibody, washed with 10 mM Tris, pH 7.5, 50 mM NaCl and 2.5 mM EDTA, and visualized using a secondary goat antimouse or anti-rabbit antibody conjugated with horseradish peroxidase. Chemiluminescence was performed with ECL (Amersham Life Science, Du È bendorf, Switzerland). The following primary antibodies were used: caspase-8 p20, (c-20, polyclonal), caspase-3, Fas (C-20)-G (polyclonal), c-Myc and Bcl-2(100) (monoclonal) from Santa Cruz Biotechnology (CA, USA) and caspase-6, -7 monoclonal antibody were purchased from Pharmingen International (CA, USA). Caspase-9 and Anti-FADD (monoclonal) from MBL (Naka-ku Naagoya, Japan).
